Replies to post #4865 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Aside from the ones you mentioned, the other DIC/sepsis programs to watch are Artisan Pharma’s ART-123 (which has been extensively discussed on this board lately) and NVS’ Tifacogin (#msg-15157973).

I’ll let someone else comment on the gram-positive vs gram-negative question because that’s not my bailiwick. Regards, Dew

[gym gravity]

Nice post. I don't know the details of the TLR-4 pathway, but on the surface, it seems like ATryn and these molecules will work on different time frames. ATryn will immediately patch a hole in the anticoagulation pathway. These TLR-4 inhibitors will be slower acting. ATryn also has a broad anti-inflammatory activity because it interacts with the endothelial cells. I think yes, both ATryn and one of these inhibitors could work well together. A short course of ATryn while in the hospital and an extended treatment with an oral anti-inflammatory agent + antibiotics?

It's also posible that ATryn is a better anti-inflammatory than these TLR-4 inhibitors.

Hopefully the very next thing we hear from GTCB is of a Japanaese partnership.